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Abstract
Introduction This comprehensive observational study aimed to gain insight into adherence to nilotinib and the effect of
(non)adherence on exposure (Cmin) and treatment outcomes.
Methods Chronic myeloid leukemia (CML) patients using nilotinib were followed for 12 months. Adherence was measured by
Medication Event Monitoring System (MEMS), pill count, andMedication Adherence Report Scale (MARS-5). Nilotinib Cmin and
patient-reported outcomes (i.e., quality of life, side effects, beliefs, satisfaction) were measured at baseline, 3, 6, and 12 months.
Results Sixty-eight patients (57.5 ± 15.0 years, 49% female) participated. Median adherence to nilotinib (MEMS and pill count)
was ≥ 99% and adherence < 90% was rare. Self-reported nonadherence (MARS-5) increased in the first year of treatment to a
third of patients. In line with the strong beliefs in the necessity of taking nilotinib, forgetting to take a dose was more prevalent
than intentionally adjusting/skipping doses. Nilotinib Cmin were generally above the therapeutic target in 95% of patients.
Patients reported a variety of side effects, of which fatigue was most frequent. The mean Cmin was higher in patients who
reported severe itching and fatigue. The overall 1-year MMR rate ranged from 47 to 71%.
Conclusion Substantial nonadherence (< 90%) to nilotinib was rare and nilotinib Cmin were generally above the therapeutic
target. Lack of response in our group of patients was not related to nonadherence or inadequateCmin. Nevertheless, a considerable
number of patients experienced difficulties in adhering to the twice daily fasted dosing regimen, emphasizing the importance of
continuous support of medication adherence in CML.
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Introduction
Newly diagnosed patients with chronic-phase chronic mye-
loid leukemia (CP-CML) are treated with tyrosine kinase in-
hibitors (TKI) including imatinib, dasatinib, nilotinib, or
bosutinib which specifically block BCR-ABL activity [1].
Dasatinib, nilotinib, and bosutinib are so-called second-gen-
eration TKIs (2G-TKIs) that are more potent than imatinib.
Clinical study data show that the overall survival of CP-CML
patients achieving a major molecular response (MMR) on TKI
treatment now resembles that of the general population [2, 3].
However, side effects like fatigue, edema, skin toxicity, accel-
erated cardiovascular disease, pleural effusion, and pulmonary
hypertension may cause significant morbidity and reduce
quality of life [4–6].
CP-CML treatment discontinuation may be attempted
in patients attaining a deep molecular response at the level
of MR4 or better [1, 7]. However, not all patients achieve
these response levels. Causes include the presence of
point mutations in the kinase domain of the BCR-ABL
protein, increased BCR-ABL protein expression, and in-
creased drug efflux mechanisms [8, 9]. In addition, phar-
macokinetic factors like interindividual variabilities in the
liver (CYP3A4) metabolism and plasma protein binding,
or interactions with other drugs, may lead to suboptimal
plasma drug concentrations that affect response rates
[10–16]. In this respect, lower trough plasma concentra-
tions (Cmin) have been associated with a failure to achieve
key response milestones and a shorter time to progression
in both newly diagnosed and imatinib-resistant or
imatinib-intolerant CP-CML patients [12–15]. On the oth-
er hand, supratherapeutic TKI levels have been shown to
increase toxicity. For example, high nilotinib peak plasma
concentrations that may occur when the drug is taken with
food may increase the QTc interval [16].
Next to these disease-related and pharmacokinetic factors,
a major factor to treatment failure is medication nonadherence
[17–22]. Several studies show that for imatinib, an adherence
rate (mostly expressed by the Medication Possession Ratio
[MPR]) of at least 90% is required to achieve an adequate
(molecular) response and that nonadherent patients have a
significantly reduced chance of reaching key response mile-
stones [17–22]. For the 2G-TKIs, data on the minimum ad-
herence required to achieve the intended medication effect are
not available. The majority of data on adherence to 2G-TKIs
have been obtained in retrospective studies [23–35], with only
one study investigating adherence prospectively [36]. The av-
erage adherence rates range from 69 to 100% [23–36]. A wide
variety of (interrelated) factors is known to influence adher-
ence in CML. They include the choice of the medication,
convenience of the dosing regimen, treatment duration, treat-
ment effectiveness, occurrence of side effects affecting quality
of life, patient beliefs, patient knowledge and understanding,
disease characteristics (e.g., disease severity, comorbidity and
comorbidity treatment, mental status), life style, communica-
tion with healthcare providers (HCP), and affordability of
treatment [37–39]. Clearly, a better understanding of the var-
iables affecting (non)adherence is necessary to optimize treat-
ment conditions to a level that enables patients to use their
prescribed medication as long as required while preserving
the highest possible quality of life [37, 38, 40].
Most CP-CML patients have to take their oral medica-
tion indefinitely. In this respect, for patients taking
nilotinib, the necessary twice daily fasted schedule is an
additional burden that may trigger nonadherence. The
RAND study (Response and Adherence to Nilotinib in
Daily practice) was conducted with the aim to gain insight
into nilotinib treatment adherence in daily clinical practice
and the effect of (non)adherence on nilotinib exposure
and treatment outcomes. Multiple measures were used to
assess adherence including electronic monitoring, pill
count and questionnaires, and factors influencing adher-
ence including patient characteristics, side effects, quality
of life, attitudes towards disease and treatment, and satis-
faction with information were studied. Furthermore, we
evaluated nilotinib exposure and its relationship with side
effects and treatment outcome.
Methods
Study design
In this multicenter prospective observational study [41], con-
ducted between August 2013 and April 2017 in six Dutch
hospitals, CP-CML patients using nilotinib were followed
for 12 months. Initially, it was the aim only to include newly
diagnosed CP-CML patients starting nilotinib treatment.
However, because of poor participant accrual, the protocol
was amended in September 2014 and patients on treatment
with nilotinib (and regardless of prior TKI treatment) were
also included. The study was registered in the Netherlands
Trial Register (NTR3992) and the protocol has been published
previously [41].
Patients
The study population consisted of patients (aged ≥ 18
years) with CP-CML using nilotinib [42]. According to
the line of treatment (first- or second/third-line) and the
type of nilotinib treatment at baseline (starting treatment
or already being on treatment), four groups of patients
were distinguished. Exclusion criterion was the inability
to grant consent.
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Data collection
Medication adherence
Medication adherence has been defined as “the process by
which patients take their medications as prescribed”, divided
into three phases: initiation, implementation, and discontinu-
ation [43]. The RAND study focused on the implementation
phase and used three methods to assess adherence to nilotinib.
First, adherence was assessed by means of a medication
event monitoring system (MEMS; AARDEX Group,
Switzerland). Capsules were stored in a bottle closed by a
lid containing the MEMS monitoring the date and time of
opening. Each opening was presumed to indicate the intake
of a dose, with a maximum of two intakes per day. Patients
knew that dosing data were compiled by means of theMEMS.
To minimize bias, patients were instructed that nilotinib use in
general was studied and the study aim ofmeasuring adherence
was deliberately omitted in the patient information.
Adherence was expressed as the proportion of days covered
(PDC) and calculated by the number of times that the bottle
had been opened divided by the total number of intakes pre-
scribed over the period that the MEMS was used times 100%.
Second, adherence was assessed by means of pill count.
Patients were contacted unannounced by the researcher by
phone at study entry and at the end of the follow-up period
to count the number of capsules at that moment. Patients were
asked whether they had returned capsules to the pharmacy or
disposed capsules in any other way. Pharmacy dispensing
records and the prescribed number of capsules retrieved from
the patient’s medical file were collected. Adherence was
expressed as the adherence rate (AR) and calculated by divid-
ing the number of capsules dispensed minus the pill count by
the number of capsules prescribed over the study period times
100% [33].
Third, the five-item Medication Adherence Report Scale
(MARS-5) was used to assess self-reported adherence
[44–46]. The MARS-5 was administered at 3, 6, and 12
months from study entry. Items are scored using a 5-point
scale (1 = always to 5 = never). Scores for each item were
summed to give a total score ranging from 5 to 25, with higher
scores indicating higher levels of adherence. A self-composed
question assessed nilotinib intake in relation to food intake.
Nilotinib intake under fasting conditions was scored as incor-
rect when patients reported to have taken nilotinib < 60 min
before or < 120 min after food intake.
Trough plasma concentration
Blood sampling was performed by the patient at home by
means of a validated dried blood spot (DBS) sampling meth-
od. Using the DBS, nilotinib plasma concentrations were cal-
culated as previously reported [47, 48]. Patients were
instructed to sample blood at predose at baseline (if already
on nilotinib treatment), 3, 6, and 12 months from study entry.
The time of blood sampling, time of last nilotinib intake, and
body weight were recorded in patient diaries. Cmin samples
were defined as those taken between 8 and 16 h after the prior
dose.
Response to treatment
The response was considered optimal when a MMR was
achieved within 12 months of nilotinib treatment [1, 42].
MMR was defined as a BCR-ABL transcript level of ≤ 0.1%
on the International Scale. For patients already on treatment at
entry, the time until MMR was obtained retrospectively from
their medical files.
Questionnaires
At study entry, patients completed a self-administered com-
posite questionnaire including demographic characteristics
(date of birth, gender, education, living status, and working
status), use of St. John’s wort, use of grapefruit (juice), quality
of life (Short Form-12 Health Survey [SF-12]), side effects,
and beliefs about medication in general (Beliefs about
Medicines Questionnaire [BMQ]-General) and specifically
about nilotinib (BMQ-Specific) [49, 50]. The questionnaire
at 3, 6, and 12 months also included the MARS-5 and ques-
tions on nilotinib intake in relation to food intake, use of tools
to prevent forgetting, illness perception (Brief Illness
Perception Questionnaire [Brief IPQ]), and information satis-
faction (Satisfaction with Information about Medicines Scale
[SIMS])[51, 52]. Education was assessed as the highest level
completed, and dichotomized into higher education (higher
general secondary education or above) and lower education.
Living status was categorized as living alone or not living
alone, and work status as having paid work or not.
Questions on side effects were based on literature data and
concerned specific nilotinib toxicities occurring in > 10% of
patients (headache, nausea, rash, itching, myalgia, fatigue)
[53]. Answers were scored on a 5-point Likert scale (0 = not
at all to 4 = very much). Symptoms scored as “3 = a lot” or “4
= very much” were considered “severe.”
Disease and treatment characteristics
Information on disease characteristics, medical history, co-
medication, and nilotinib treatment was obtained from the
patient’s medical file and pharmacy dispensing record.
Statistical analysis
Differences in patient and clinical characteristics between the
four groups were tested (continuous variables by Mann-
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Whitney tests and categorical variables by chi-square tests).
Adherence was summarized by median and mean PDC
(MEMS), AR (pill count), and MARS-5 scores, and the num-
ber of nonadherent patients according to various adherence
cut-off points. Agreement between the adherence measures
was examined using intra-class correlation coefficient (ICC,
two-way mixed effects model) comparing MEMS (% PDC)
with pill count (% AR) and Cohen’s Kappa comparing
MEMS and pill count (dichotomized at thresholds of 90%
and 95%) with MARS-5. Change over time in dichotomized
MARS-5 scores was assessed using generalized estimating
equation (GEE) and univariable logistic regression was used
to identify variables (one by one) related to self-reported
nonadherence (MARS-5 < 25 at 12months). Variables related
to incorrect intake of nilotinib under fasting conditions were
identified using logistic regression (baseline characteristics)
and GEE (repeatedly measured variables).
Individual measures of exposure were obtained using av-
eraged Cmin values for individual patients based on the mea-
surements obtained at baseline, 3, 6, and 12 months. Intra-
patient variability in nilotinib Cmin was analyzed in patients
who had ≥ 2 analyzed samples available and expressed as the
average coefficient of variation (CV%). Missing Cmin values
were imputed with the mean of the observed Cmin values for
the corresponding dose. Univariable linear regression was
used to identify variables (one by one) related to nilotinib
Cmin. GEEwas used to identify whether the occurrence of side
effects was related to observed nilotinib Cmin values (without
imputation) obtained at baseline, 3, 6, and 12 months.
Comparison of adherence (continuous) and Cmin values
(either grouped into quartiles [Q1 vs. Q2–Q4] or based on a
previously reported [13] threshold concentration of 490 μg/L)
among response groups (time to MMR after start of nilotinib
treatment ≤ 12 months vs. > 12 months, stratified by line of
treatment) was performed using Mann-Whitney tests and
Fisher’s exact tests. Time to MMR was assessed using the
Kaplan Meier method with logrank test. In these outcome
analyses, the mean of each measure of adherence and Cmin
values was used. For all analyses, a two-tailed significance
level of 0.05 was used. p values below this level were consid-
ered statistically significant. All statistical analyses were per-




A total of 68 patients (mean age 57.5 ± 15.0 years, 49% fe-
male) were included. Thirty-five patients (51%) received first-
line nilotinib treatment, of whom 20 (29%) started treatment
(subpopulation 1A) and 15 (22%) already were on treatment
at baseline with a median duration of 40 months (range 7–51)
(subpopulation 1B). Thirty-three patients (49%) received
second/third-line nilotinib treatment, of whom 9 (13%) started
treatment (subpopulation 2A) and 24 (35%) already were on
treatment at baseline with a median duration of 43 months
(range 7–51) (subpopulation 2B). Fifteen patients (22%)
discontinued nilotinib treatment during the study period due
to side effects (n = 6), progression (n = 4), entering treatment-
free remission (n = 4), or death (n = 1). Their characteristics
(demographics, medical history, nilotinib dose) did not differ
from those of patients who completed follow-up. Five patients
dropped out before assessment at 3 months, two patients be-
fore 6 months, and eight patients before 12 months. Figure 1
provides information on the number of patients for whom data
are available.
Patient characteristics
Patients’ characteristics are presented in Table 1. There were
no statistically significant differences (p > 0.05) with regard to
patient demographics, medical history, and nilotinib dose be-
tween the four subpopulations, except for a small difference in
the median number of co-medications between subpopula-
tions 1A/1B and 2A/2B (1 vs. 3, p = 0.043). Most patients
(49/68, 72%) used the recommended dose of 300 mg BID.
The other patients used a dose of 150 mg BID (n = 5), 400 mg
BID (n = 9), 300 mg QD (n = 2), and 400 mg QD (n = 3). In
three patients, the dose was reduced during the study period.
The percentage of patients with co-medication was 73%. No
patient reported using St. John’s wort. Based on the declared
co-medications, there were no drug-drug interactions.
Patients’ SF-12 scores for physical health measured at 6
months ranged from 17.1 to 58.4 (standardized scale 0–100
[Supplementary Table S1]). The median and mean scores
were 45.4 and 44.1 ± 11.5, respectively. The SF-12 scores
for mental health ranged from 27.3 to 61.8, with median and
mean scores of 40.0 and 41.8 ± 6.9, respectively. About 75%
of the patients experienced fatigue, which was severe in 20%
(Supplementary Table S1). Rash, itching, and myalgia were
reported by 43%, 59%, and 54% of the patients, respectively,
and 8%, 8%, and 6% indicated these symptoms as severe.
Headache and nausea were less common and generally mild.
The BMQ scores indicated that patients had strong beliefs
about the necessity of taking nilotinib (20.5 ± 3.4) and low
concerns about CML and the potential adverse effects of
nilotinib (12.9 ± 3.4). The majority of patients had an
accepting (65%) or ambivalent (30%) attitude towards
nilotinib (Supplementary Table S1). Regarding illness percep-
tion, the high medians on the timeline (10/10), treatment con-
trol (10/10), and coherence (8/10) subscales indicate that pa-
tients were fully aware of the lifelong duration of CML,
strongly believed in the effectiveness of nilotinib, and felt a
strong coherent understanding of CML. The low median on
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the emotional response (3/10) subscale indicated that patients
perceived only little emotional distress from CML.
Adherence to nilotinib treatment
Data on adherence to nilotinib treatment are shown in Table 2.
Adherence by means of MEMS was available for 42 patients,
and monitored over a mean of 307 ± 113 days. Eight patients
were not willing to use MEMS (as it would disturb their daily
routines too much), three patients did not return their MEMS,
and eleven patients returned MEMS with no data (either due
to MEMS malfunction or patient refusal). Four patients
discontinued nilotinib treatment within 4 days from study en-
try. The median and mean PDC from baseline to follow-up
were 99.0% and 95.7 ± 8.5%, respectively (from 54.6 to
100%). Five patients (5/42, 12%) covered less than 90% of
days observed. Adherence by means of pill count could be
determined for 50 patients. For the remaining patients, the pill
count was missing (n = 9), pharmacy data were incomplete (n
= 5), or treatment was stopped within 4 days from study entry
(n = 4). The median and mean AR were 99.8% and 98.3 ±
8.7%, respectively (from 67.3 to 125.6%). Five patients (5/50,
10%) had an AR < 90%. Five patients (5/50, 10%) had an AR
> 105%.
The percentage of patients reporting nonadherence on any
of the five MARS-5 statements after 12 months was 32%.
Median and meanMARS-5 scores of the nonadherent patients
were 24 and 23.3 ± 1.0, respectively. The most common state-
ment was “I forget to take it” varying from 17 to 26%. The
statements “I alter the dose,” “I stop taking it for a while,” and
“I decide to miss out on a dose” were reported by ≤ 6%.
Seventeen patients (27%) did not always correctly take
nilotinib under fasting conditions (i.e., < 60 min before or <
120 min after food intake). No patient reported to have taken
nilotinib simultaneously with food or to have used grapefruit
(juice) during nilotinib treatment. Most patients (87%) report-
ed to have used a tool to remind them of the scheduled
nilotinib intake (e.g., fixed place/moment, alarm, diary, sup-
port from family/friends).
Agreement between MEMS (% PDC) and pill count (%
AR) was poor, with an ICC of 0.14 (p = 0.801) (Table 2).
Regarding dichotomized MARS-5 scores (25 vs. < 25), only
adherence by means of MEMS dichotomized at a threshold of
95% showed moderate agreement, with Cohen’s Kappa vary-
ing from 0.29 to 0.47 (p < 0.1).
The number of patients reporting nonadherence (MARS-5
data) increased over time for patients starting nilotinib first-
line treatment (subpopulation 1A) from 8% after 3 months of
treatment to 33% after 12 months. In the other three subpop-
ulations, the percentage of patients ranged from 27 to 37%.
This group-by-time interaction effect was close to significance











































































































Study dropout T1 : 3 (4%)
T2 : 0 (0%)
T3 : 3 (4%)
T1 : 0 (0%)
T2 : 1 (2%)
T3 : 1 (2%)
T1 : 1 (2%)
T2 : 1 (2%)
T3 : 3 (4%)
T1 : 1 (2%)
T2 : 0 (0%)
T3 : 1 (2%)
T1 : 5 (7%)
T2 : 2 (3%)
T3 : 8 (12%)
Fig. 1 RAND study flow chart
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with differences in disease and treatment characteristics, oc-
currence of side effects, and SF-12, Brief IPQ, BMQ-Specific,
and SIMS scores (Supplementary Table S2). Regarding de-
mographics, only gender was associated with self-reported
nonadherence. Female patients more often reported
nonadherence (44% vs. 13% in male patients, OR 5.1,
95%CI 1.2–22.2, p = 0.029). As only few patients had an
PDC (MEMS data) or AR (pill count data) below 90%, no
Table 1 Patient demographics





Age, mean ± SD (years) 55.7 ± 15.0 59.3 ± 14.9
Female gender, n (%) 15 (43%) 18 (55%)
Higher level of education, n (%) 7 (20%) 12 (36%)
Living alone, n (%) 7 (20%) 2 (6%)
Employed, n (%) 18 (51%) 12 (36%)
Medical history
History of other malignancy, n (%) 7 (20%) 7 (21%)
Presence of comorbidity, n (%) 16 (46%) 22 (67%)
Co-medication, range, median (IQR) * 0–12, 1 (0–4) 0–11, 3 (1–5)
No. of patients with ≥ 1 co-medication 22 (63%) 28 (85%)
History of CML and treatment
Years since CML diagnosis, range, median (IQR) 1–4, 3.4 (1.2–3.9)a 1–22, 7.6 (5.0–10.5)
Prior TKI treatment and outcome, n (%)




Dasatinib NA 12 (36%)
Failure 4 (33%)
Intolerance 8 (66%)
Disease parameters at baseline
Hematological response, n (%)
Too early to judge 20 (57%) -
CHR 13 (37%) 29 (88%)
No CHR 2 (6%) 3 (9%)
Not documented - 1 (3%)
Molecular response, n (%)
Too early to judge 20 (57%) -
MR4 (BCR-ABL ≤ 0.01%) 10 (29%) 10 (30%)
Major MR (BCR-ABL ≤ 0.1%) 1 (3%) 9 (27%)
BCR-ABL > 0.1% 3 (9%) 10 (30%)
Not documented 1 (3%) 4 (12%)
Nilotinib treatment at baseline
Months on nilotinib, range, median (IQR) 7–51, 40 (15–46)a 4–92, 43 (25–55)a
Dose 300 mg/day, n (%) 2 (6%) 5 (15%)
400 mg/day, n (%) - 3 (9%)
600 mg/day, n (%) 32 (91%) 17 (52%)
800 mg/day, n (%) 1 (3%) 8 (24%)
Abbreviations: CHR, complete hematological response; CML, chronic myeloid leukemia; IQR, interquartile
range; MR, molecular response; NA, not applicable; SD, standard deviation; TKI, tyrosine kinase inhibitor
*Difference between groups significant (p ≤ 0.05)
a Patients already being on treatment at baseline, n = 15 (1st line) n = 24 (≥ 2nd line)
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factors could be analyzed for their relationship with
nonadherence as assessed by MEMS or pill count. No associ-
ation was found between all variables and incorrect intake of
nilotinib under fasting conditions (Supplementary Table S2).
Nilotinib Cmin
A total of 178 DBS samples were collected by 61 patients.
Thirty-five samples (19.7%) were rejected because the spot
size was too small for analysis. Six samples (3.4%) had been
obtained within 8 h of nilotinib intake and therefore were
excluded as Cmin [48]. As the result, 137 Cmin values from
56 patients were obtained (Table 3). Forty-two patients (72%)
had ≥ 2 analyzed samples available, and the %CV in Cmin
amounted to 25 ± 19% (median 20%; range 1–91%). No as-
sociation was found between all measures of adherence and
nilotinib Cmin (Table 3). Age, gender, body weight, incorrect
intake of nilotinib under fasting conditions, and intra-patient
variability were also not significantly related to the nilotinib
Cmin. A positive linear association between nilotinib dose and
Cmin was found (β = 0.44, p < 0.001).
The relationship between the nilotinib Cmin value and
patient-reported side effects is presented in Table 4. The mean
Cmin was significantly higher in patients who reported severe
itching (p = 0.012) and fatigue (p = 0.023). With regard to
fatigue, there was a significant difference in Cmin between pa-
tients reporting any severity fatigue and those without fatigue (p
= 0.007). The median nilotinib dose was 600 mg in all side
effect groups. No relationship with other side effects was found.
Molecular response to nilotinib treatment
For patients on first-line nilotinib treatment (subpopulations
1A/1B), the 1-year MMR rate was 71% (20/28) (note, four
Table 2 Adherence to nilotinib
treatment Mean ± SD Median (IQR) Range
Adherence by means of MEMS (n = 42)
PDC, from baseline to follow-up 95.7 ± 8.5 99.0 (95.6–99.6) 54.6–100
100% 6 (14.4%)
≥ 95–< 100% 27 (64.3%)
≥ 90–< 95% 4 (9.5%)
< 90% 5 (11.9%)
Adherence by means of pill count (n = 50)
AR, from baseline to follow-up 98.3 ± 8.7 99.8
(96.4–101.6)
67.3–125.6
> 105% 5 (10.0%)
≥ 95%–≤ 105% 35 (70.0%)
≥ 90–< 95% 5 (10.0%)
< 90% 5 (10.0%)
Adherence by means of MARS-5 (n = 56)
MARS-5 Sum Score (5–25) 24.5 ± 1.0 25 (24–25) 21–25
MARS-5 Sum Score < 25 18 (32.1%)
Agreement of adherence assessment methodsa
Pill count (continuous) (n = 36)
ICC p
MEMS (continuous) 0.14 .801
MARS-5 (dichotomous, < 25 vs. 25) (n = 34mems; n = 38pill count)
K p
MEMS (dichotomous) < 90% vs. ≥ 90% 0.04 .778
< 95% vs. ≥ 95% 0.41 .014
Pill count (dichotomous) < 90% vs. ≥ 90% − 0.03 .854
< 95% vs. ≥ 95% − 0.04 .782
Abbreviations: AR, adherence rate; MARS-5, Medication Adherence Report Scale, at ≥ 12 months of treatment;
MEMS, Medication Event Monitoring System; PDC, proportion of days covered; SD, standard deviation; IQR,
interquartile range; ICC, intra-class correlation coefficient; K, Kappa
a Analyses of continuous outcomes using ICC and dichotomous outcomes using Cohen’s Kappa
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missing). Themedian andmean times toMMR12 were 6.1 and
5.9 ± 3.2 months, respectively (range 1.2–12.9 months). Two
patients discontinued nilotinib treatment before achieving a
MMR due to side effects and one patient died. For patients
on second/third-line nilotinib treatment (subpopulations 2A/
2B), the 1-year MMR rate was 47% (7/15) (note, four
missing). The median and mean times to MMR12 were 3.7
and 5.8 ± 4.4 months, respectively (range 2.6–12.4 months).
One patient discontinued nilotinib treatment before achieving
a MMR due to side effects. Thirteen patients had achieved a
MMR prior to nilotinib treatment, of whom seven patients a
deep MR4.
Table 3 Associations with
nilotinib Cmin Observed nilotinib Cmin (μg/L) Mean ± SD Median (IQR) Range
400 mg BID (n = 25) 1497 ± 597 1253 (1054–2053) 342–2540
300 mg BID (n = 85) 1021 ± 472 954 (654–1274) 196–2413
150 mg BID (n = 15) 835 ± 412 656 (548–1042) 390–1793
400 mg QD (n = 6) 536 ± 57 552 (517–570) 422–574
300 mg QD (n = 6) 567 ± 110 589 (450–658) 418–702
Associations with nilotinib Cmin
a β p
Age 0.08 .534
Female gender 0.05 .687
Body weight 0.03 .982
Dose 0.44 < .001
CV% 0.23 .154
Incorrect intake under fasting conditionsb T1 − 0.07 .712
T2 − 0.01 .949
T3 0.21 .297
Adherence to nilotinibb MEMS − 0.05 .763
Pill count − 0.13 .396
MARS-5 T1 0.13 .466
MARS-5 T2 0.05 .753
MARS-5 T3 − 0.14 .472
Abbreviations: BID, twice daily; QD, once daily; Cmin, trough plasma concentration; CV%, coefficient of varia-
tion;MARS-5, Medication Adherence Report Scale;MEMS, Medication Event Monitoring System; SD, standard
deviation; IQR, interquartile range. Significant relations are shown in italic (p < 0.05)
a BID dosing, Cmin samples were taken between 8 and 16 h after the prior dose (n = 125)
b Incorrect intake of nilotinib under fasting conditions andMARS-5 was related to observedCmin values at 3 (T1),
6 (T2), and 12 (T3) months from baseline
Table 4 Nilotinib Cmin and
patient-reported side effects of
nilotiniba








Headache 91 970 (618–1288) 40 905 (625–1254) 1 2413 .964 -
Nausea 104 945 (615–1249) 27 1210 (750–1798) 1 648 .151 -
Rash 75 964 (598–1338) 45 966 (719–11620 12 1157 (764–1540) .418 .746
Itching 61 954 (565–1283) 61 923 (740–1243) 11 1260 (1021–1800) .938 .012
Myalgia 56 857 (574–1219) 62 1031 (765–1380) 12 840 (658–1553) .387 .399
Fatigue 32 777 (561–1087) 72 974 (644–1373) 25 1160 (787–1468) .007 .023
Abbreviations: Cmin, trough plasma concentration; IQR, interquartile range. Significant relations are shown in
italic (p < 0.05)
a Analyses using generalized estimated equations (GEE)
b Side effects scored as “a little bit”/”rather” were considered “mild”; side effects scored as “a lot”/”very much”
were considered “severe”
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Patients who achieved a MMRwithin 12 months after hav-
ing started nilotinib treatment had similar adherence rates
(mean PDC 95.0 ± 8.7%) as those who failed to obtain a
MMR within 12 months of treatment (mean PDC 94.6 ±
11.9%, p = 0.683) (Table 5). Among patients treated with
either first-line or second/third-line nilotinib, no significant
differences in mean adherence were found between the re-
sponse groups. There were no significant differences between
response groups in self-reported adherence (MARS-5) (data
not shown).
Among the evaluable patients, the MMR rate was not sig-
nificantly different between Cmin quartiles (Table 5). The me-
dian time to MMR12 was 6.4 (Q1, n = 5), 6.7 (Q2, n = 7), 4.3
(Q3, n = 12), and 2.8 months (Q4, n = 3), and was not statisti-
cally different among the quartile groups (p = 0.098). Nine
patients (16%) had a Cmin below the threshold concentration
of 490 μg/L at any time (range 196–467), of whom six patients
(11%) once and two patients (4%) twice. One patient (2%) had
four Cmin values below 490 μg/L. These patients did not differ
in time to MMR12 from those with Cmin above 490 μg/L.
Discussion
This comprehensive observational study in CP-CML patients
using nilotinib aimed to obtain insight into their adherence to
treatment and its influence on drug exposure and treatment
outcomes. The median adherence to nilotinib was high (≥
99%) and adherence lower than 90% was rare. Nevertheless,
after 12 months of treatment, about a third of the patients
reported occasional nonadherence. In line with the high belief
of patients in the necessity of taking nilotinib, forgetting to
take a dose was more prevalent than intentionally adjusting or
skipping doses. Although the intra-patient variability was
high, nilotinib Cmin values were generally above the therapeu-
tic target in 95% of patients. Patients reported a variety of side
effects, of which fatigue was most frequent. The mean Cmin
was higher in patients who reported severe itching and fatigue.
Several studies assessing patients’ adherence to nilotinib
using objective measures reported generally lower rates of
adherence [23–35]. However, various methodological issues
(i.e., study design and setting, follow-up period, assessment
measure) limit comparison across studies [37, 54, 55].Most of
the studies were retrospective using claims data or pharmacy
refill data [23–32, 35]. The sample sizes of these studies were
larger and its data gathered unobtrusively without patient in-
volvement. In the present study, nonadherent patients may
have been less willing to participate which may lead to an
over-estimation of adherence. In addition, studies using claims
data or pharmacy refill data may underestimate the level of
adherence because dose reductions are generally not taking
into account in time. As yet prospectively obtained data are
limited to those of ten patients participating in the TAKE-IT
study investigating adherence by means of MEMS in CP-
Table 5 Adherence, Cmin, and molecular response to nilotinib treatment
Adherence and molecular response to nilotinib treatment
Adherence using MEMS Adherence using pill count
n Mean ± SD p n Mean ± SD p
All patients .683 .927
Optimal response 15 95.0 ± 8.7% 21 96.9 ± 11.0%
Suboptimal response 11 94.6 ± 11.9% 12 99.0 ± 2.6%
Subpopulation 1A/1B (1st line treatment) .441 .444
Optimal response 11 97.0 ± 5.0% 14 97.3 ± 9.9%
Suboptimal response 5 93.9 ± 13.1% 6 100.7 ± 1.2%
Subpopulation 2A/2B (≥ 2nd line treatment) .352 .731
Optimal response 4 88.0 ± 22.3% 7 96.0 ± 13.8%
Suboptimal response 6 95.9 ± 3.7% 6 97.3 ± 2.6%
Nilotinib Cmin and molecular response to nilotinib treatment
1-year MMR rate according to nilotinib cmin p
Q1 Q2 Q3 Q4 Q1 vs. Q2–Q4
All patients 56% (5/9) 88% (7/8) 75% (12/16) 30% (3/10) .706
Subpopulation 1A/1B (1st line treatment) 71% (5/7) 100% (5/5) 73% (8/11) 40% (2/5) .999
Subpopulation 2A/2B (≥ 2nd line treatment) 0% (0/2) 75% (2/3) 80% (4/5) 20% (1/5) .467
Abbreviations: Cmin, trough plasma concentration; MEMS, Medication Event Monitoring System; SD, standard deviation; Q, quartile
Optimal and suboptimal responses were defined as time to major molecular response ≤ 12 months and > 12months, respectively.Cmin quartiles were Q1
(< 635 μg/L), Q2–Q3 (635–< 1346 μg/L), Q4 (≥ 1346 μg/L)
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CML patients using imatinib, dasatinib, or nilotinib [36, 56].
Although the median overall adherence (97.5%) for all TKI
was similar to that found in the present study, adherence was
somewhat lower in patients treated with nilotinib as compared
with imatinib and dasatinib.
In accordance with the findings of a recent review compar-
ing MEMS with pill count and self-report [54], in the present
study, there was poor agreement between adherence as
assessed by these measures. In 81% of the studies reviewed,
a significant difference between the rates obtained by applying
each of these measures was found [54]. Clearly, each measure
obtains its data differently and identifies different components
of adherence. Since MEMS provides detailed, objective data
on adherence, it is most often considered to be the gold stan-
dard [57]. However, the use of this system is known to influ-
ence adherence [57]. Moreover, as the MEMS solely records
the opening of the container, evidence that (the full dose of)
medication is actually ingested is not provided [57]. The pill
count method is less interfering than the use of MEMS but
fails to provide insight into adherence patterns [55, 58].
Likewise, it does not provide evidence that medication is ac-
tually taken. Subjective measures generally provide explana-
tions for nonadherence; however, results can be biased by
patients giving false information [55, 58]. Therefore, a com-
bination of objective and subjective measures is considered
the best solution to assess medication adherence [55, 58].
Although the adherence over the full study period was
high, occasional nonadherence measured with MARS-5 in-
creased in the first year of nilotinib treatment to a third of
the patients. This finding is consistent with the results of other
studies [39, 59, 17]. Over time, patients become accustomed
to living with a chronic disease and taking medication daily.
Due to apparently successful treatment, patients increasingly
participate in social and occupational activities. However, this
often interferes with their daily routines which makes patients
more easily to forget or skip a dose [39, 59, 60, 17]. On the
other hand, intentional nonadherence is mostly due to percep-
tual barriers (i.e., beliefs) [61, 62]. In the present study, for-
getting to take nilotinib was found to be more prevalent than
intentionally skipping or adjusting a dose and could be ex-
plained by the strong beliefs of patients in the necessity of
taking nilotinib. The seriousness of the disease and clinical
importance of TKI treatment are likely to reflect a patients'
perceived need for treatment [63]. HCP should encourage CP-
CML patients using nilotinib to use practical aids (such as
alarm devices and pill boxes) in order to avoid forgetting their
medication as part of measures that prevent adherence to de-
cline over time. In line with the results of a recently published
worldwide patient survey by the CML Advocates Network
[39], in the present, study female patients reported
nonadherence more often than male patients.
A quarter of the patients did not consistently follow the
recommendation to take nilotinib at least 1 h before or 2 h
after a meal [53]. Food substantially increases nilotinib bio-
availability [16, 64] which may cause adverse events [12].
Clearly, patients should be supported in correctly taking
nilotinib in order to avoid potentially hazardous nilotinib con-
centrations. On the other hand, by applying a lower dose, the
food-dependent bioavailability of nilotinib can be used to im-
prove intake conditions [64]. As this simplified dosing regi-
men is likely to promote adherence and quality of life, its
usefulness in daily practice should be further explored [64].
The prevalence rates of headache, nausea, rash, itching,
and myalgia found in the present real-world study were essen-
tially similar to those found in the ENESTnd trial [65]. Fatigue
was reported by about one-fifth of the patients in this trial [65].
In contrast, in the present study, this debilitating side effect
was reported by about three quarters of the patients. The lower
prevalence of fatigue in the ENESTnd trial [65] might be
explained by the propensity of HCP to underestimate symp-
tomatic, subjective side effects [66, 67]. Our findings are in
line with those of other studies providing data on patient-
reported side effects [68–70]. Although nilotinib side effects
are generally mild, they do adversely impact the patients’
quality of life [71, 68, 72]. Considering the long duration of
CML treatment and increased risk of treatment interruption,
discontinuation, or switching due to side effects, it is impor-
tant to actively inquire after (perceived) side effects and sub-
sequently support patients in mitigating their effects [73].
Remarkably, the mean Cmin of nilotinib was higher in patients
reporting severe itching and fatigue. As yet higher nilotinib
Cmin have only been associated with the occurrence of all-
grade elevations in total bilirubin and lipase levels and in-
creases in QTc changes [12, 13]. Therapeutic drug monitoring
(TDM) may prevent the emergence of potentially hazardous
nilotinib plasma concentrations. On the other hand, in certain
patients with higher Cmin, the dose might be reduced on the
basis of TDM without compromising treatment efficacy.
CML patients vary greatly in their responses to treatment.
In the present study, 71% of the patients on first-line nilotinib
treatment achieved a 1-year MMR rate. This is higher than the
55% rate reported in the 5-year update of the ENESTnd trial
[65]. In this study of highly adherent patients, we could not
identify whether a lack of adherence contributed to a lack of
response. The same applied for nilotinib blood levels, which
were generally above the minimum therapeutic target.
Apparently, in this group of patients, the incapacity to achieve
a MMR during 1 year of treatment seemed not related to
nonadherence or inadequate nilotinib blood levels. However,
the underpowering of the study due to the unavoidable het-
erogeneity of its study population precludes any definitive
conclusions.
The present study has some strengths and limitations. A
major strength is its prospective design that provides a unique
and complete survey of nilotinib treatment in daily practice. A
wide range of variables was longitudinally collected by means
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of questionnaires, blood sampling, adherence measures, and
data retrieved from medical files and pharmacy records. To
our knowledge, this is the first study in which these real-life
nilotinib data have been evaluated together. Another strength
is the assessment of medication adherence, which was pro-
spectively implemented using both objective and subjective
measures. Also, it includes a long follow-up of 12 months.
Unfortunately, in the Netherlands, the number of patients
treated with nilotinib is relatively small resulting in a poor
initial accrual of newly diagnosed CP-CML patients.
Consequently, the study protocol had to be amended to in-
clude both patients already treated with nilotinib treatment
and those with prior TKI treatment. Selection bias may have
occurred, as nonadherent patients may have been less willing
to participate. In addition, patients willing to participate may
be more attentive to treatment, resulting in optimal responses,
adherence, and nilotinib blood levels in our group of patients.
Caution should be used when generalizing the findings to
other CML patients. The inability to collect adherence data
at treatment onset in patients already on nilotinib treatment
(subpopulations 1B/2B) may have biased the results of the
adherence-outcome analyses as mean adherence values were
used, whereas our analyses showed that self-reported
nonadherence increased over time in subpopulation 1A.
Another limitation is the amount of missing data. In order to
minimize their influence on outcomes, we have decided to
limit imputation to the exposure-outcome and exposure-
factors analyses.
Conclusion
Although in most patients in the present study the extent of
nonadherence to nilotinib appeared not to be clinically rele-
vant with respect to achieving an optimal response, it is clear
that a considerable number of patients experienced difficulties
in adhering to the recommended twice daily fasted dosing
regimen. Current clinical practice may be improved by foster-
ing the intention to adhere and by encouraging patients to use
practical aids that are particularly relevant to avoid the occur-
rence of unintentional nonadherence. Since adherence de-
creases by treatment duration, interventions aimed at long-
term correct use of nilotinib are also relevant. Furthermore,
HCP should inquire after (perceived) side effects and take
adequate measures to mitigate these effects, in particular the
occurrence of fatigue. TDM whether or not in combination
with dose reduction may be considered in order to avoid un-
necessary high blood levels causing severe side effects.
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